Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017, University of Oxford
Raising 'good' cholesterol fails to protect against heart disease. Credit: Shutterstock

Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal JAMA Cardiology.

There are two types of cholesterol in the blood: LDL-C, so-called 'bad' cholesterol, which is carried in low-density lipoproteins (LDL), and HDL-C, so-called 'good' cholesterol which is found in high-density lipoproteins (HDL).

Lowering LDL-C (e.g. by statins) has been demonstrated to reduce the risk of heart diseases and stroke, but the causal role of HDL-C is less clear even though observational studies have shown an inverse association between HDL-C and risk of cardiovascular diseases.

Cholesterol ester transfer protein (CETP) transfers cholesterol between different lipoproteins. Blocking this protein, which raises levels of HDL-C as well as causing other changes to blood lipids, is a potentially important approach for prevention and treatment of cardiovascular diseases. Genetic variants which alter the activity of CETP can mimic some of the effects of drugs which target this protein and can be used to help assess the potential benefits and harms of this cholesterol-modifying treatment.

Researchers at the University of Oxford, Peking University and Chinese Academy of Medical Sciences explored the health effects of CETP genetic variants, including an East Asian specific functional variant, in 150,000 Chinese adults enrolled into the China Kadoorie Biobank (CKB). After ten years of follow-up, over 5,000 study participants had and 19,000 had a stroke.

The researchers found that CETP genetic variants raised levels of HDL-C substantially, but did not lower LDL-C and did not lower the risk of cardiovascular diseases such as heart disease and stroke. There was also no effect on atherosclerotic plaques and thickness of the arteries, or on other conditions such as diabetes and kidney disease. However, the study found increased risk of eye diseases as a possible adverse effect of CETP inhibition, a finding which is supported by other genetic studies in East Asian and Western populations.

In this study of genetic variants which alter CETP activity, raising HDL-C without also lowering LDL-C did not result in a benefit for heart disease or stroke. The study results complement findings from the recent REVEAL clinical trial of the CETP inhibitor anacetrapib, which found that beneficial effects of CETP inhibition for were more likely to be due to lowering 'bad' cholesterol LDL-C than raising 'good' HDL-C.2.

New treatments are discovered by exploring biological pathways that cause disease but can be modified by drugs. The journey from basic biology to large-scale randomised trials in humans is long and expensive: the estimated cost of getting a single product to market is over $2 billion. Using genetic data to predict the benefits and harms of new treatments can reduce costs and improve the drug development pipeline.

This approach is likely to become much more widely used to examine the causal nature of biological pathways involved in diseases before mounting large-scale clinical trials in the future. Many thousands of functional genetic variants are known which may represent potential drug targets in different biological pathways, and the research teams are using the same approach to assess a number of other important therapeutic targets.

Study author Dr Iona Millwood, from the University of Oxford, said: "Our research has helped clarify the role of different types of , and suggests that raising levels of HDL-C by blocking CETP activity, without also lowering LDL-C, does not confer any major benefits for cardiovascular disease."

Professor Liming Li, study co-author from Peking University, said: "CKB is a powerful resource for collaborative research that can inform not only the relevance of lifestyle factors (e.g. smoking, diet and physical activity) for health but also drug development."

Professor Zhengming Chen, study co-author at the University of Oxford, added: "This study demonstrates the value of large prospective biobank studies with genetic data linked to health records, carried out in diverse global populations, to predict the potential benefits or harms of new drug treatments."

The full paper, "Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults," is published in the journal JAMA Cardiology.

Explore further: Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins

More information: Iona Y. Millwood et al. Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults, JAMA Cardiology (2017). DOI: 10.1001/jamacardio.2017.4177

Related Stories

Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins

August 29, 2017
Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, lowers the risk of heart attack and related cardiovascular complications in patients receiving intensive statin treatment, according to late-breaking ...

New genetic research can significantly improve drug development

June 15, 2016
According to a new study published in the International Journal of Epidemiology this week, genetic research in large-scale prospective biobank studies can significantly improve the drug development pipeline and reduce costs.

Evacetrapib impacts cholesterol but doesn't reduce cardiovascular events

April 3, 2016
Cleveland Clinic researchers studying evacetrapib have shown that despite reducing levels of low-density lipoprotein (LDL, or "bad" cholesterol) by 37 percent and raising levels of high-density lipoprotein (HDL, or "good" ...

Experimental drug raises 'good' cholesterol, may help control diabetes

July 18, 2011
A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American ...

Recommended for you

As body mass index increases, blood pressure may as well

August 17, 2018
Body mass index is positively associated with blood pressure, according to the ongoing study of 1.7 million Chinese men and women being conducted by researchers at the Yale Center for Outcomes Research and Evaluation (CORE) ...

Gout could increase heart disease risk

August 17, 2018
Having a type of inflammatory arthritis called gout may worsen heart-related outcomes for people being treated for coronary artery disease, according to new research.

Stroke patients treated at a teaching hospital are less likely to be readmitted

August 17, 2018
Stroke patients appear to receive better care at teaching hospitals with less of a chance of landing back in a hospital during the early stages of recovery, according to new research from The University of Texas Health Science ...

Cardiovascular disease related to type 2 diabetes can be reduced significantly

August 16, 2018
Properly composed treatment and refraining from cigarette consumption can significantly reduce the risk of cardiovascular disease resulting from type 2 diabetes, according to a study published in the New England Journal of ...

Genomic autopsy can help solve unexplained cardiac death

August 15, 2018
Molecular autopsies can reveal genetic risk factors in young people who unexpectedly die, but proper interpretation of the results can be challenging, according to a recent study published in Circulation.

Neonatal pig hearts can heal from heart attack

August 15, 2018
While pigs still cannot fly, researchers have discovered that the hearts of newborn piglets do have one remarkable ability. They can almost completely heal themselves after experimental heart attacks.

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

MR166
not rated yet Nov 16, 2017
The most important factor is lowering triglycerides via a low glycemic index diet. That means not eating milled grain products, white potatoes, sugar and rice. Do that and all of the lipids, blood sugar numbers and weight will fall into place naturally. Food cravings will disappear. If it has a glycemic index above 50 do not eat it.
MR166
not rated yet Nov 16, 2017
Poor lipid and triglyceride levels are just an indicator of poor diet. Hiding the indicators does not cure the problem.
MR166
not rated yet Nov 16, 2017
Also inflammation, wherever it occurs in the body including the gums is a huge factor in artery disease. The statin pushers never mention this.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.